Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:MNPR NASDAQ:NVCT NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.52+1.7%$5.25$2.25▼$7.09$614.98M2.211.76 million shs1.66 million shsMNPRMonopar Therapeutics$80.13-2.9%$59.18$4.50▼$105.00$509.39M1.4287,597 shs70,319 shsNVCTNuvectis Pharma$6.17+1.3%$6.29$4.44▼$11.80$155.03M-0.2991,770 shs62,110 shsSNDLSNDL$2.33-2.1%$2.44$1.15▼$2.89$625.41M3.834.56 million shs3.95 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-6.15%-0.47%+25.69%+49.07%+2.07%MNPRMonopar Therapeutics-8.69%-18.23%+44.84%+77.62%+1,469.58%NVCTNuvectis Pharma0.00%+1.33%-1.93%-21.92%-7.73%SNDLSNDL-4.03%-15.60%-4.80%+54.55%+19.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.52+1.7%$5.25$2.25▼$7.09$614.98M2.211.76 million shs1.66 million shsMNPRMonopar Therapeutics$80.13-2.9%$59.18$4.50▼$105.00$509.39M1.4287,597 shs70,319 shsNVCTNuvectis Pharma$6.17+1.3%$6.29$4.44▼$11.80$155.03M-0.2991,770 shs62,110 shsSNDLSNDL$2.33-2.1%$2.44$1.15▼$2.89$625.41M3.834.56 million shs3.95 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-6.15%-0.47%+25.69%+49.07%+2.07%MNPRMonopar Therapeutics-8.69%-18.23%+44.84%+77.62%+1,469.58%NVCTNuvectis Pharma0.00%+1.33%-1.93%-21.92%-7.73%SNDLSNDL-4.03%-15.60%-4.80%+54.55%+19.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.67Moderate Buy$16.00145.40% UpsideMNPRMonopar Therapeutics 3.00Buy$105.6731.87% UpsideNVCTNuvectis Pharma 2.50Moderate Buy$15.33148.51% UpsideSNDLSNDL 2.00Hold$4.5093.13% UpsideCurrent Analyst Ratings BreakdownLatest NVCT, MNPR, SNDL, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$125.0010/13/2025CMPSCOMPASS PathwaysBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $14.0010/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$125.0010/10/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NVCTNuvectis PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SNDLSNDLWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.009/29/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$70.00 ➝ $105.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ASNDLSNDL$671.81M0.91N/AN/A$3.15 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.840.00N/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.330.00N/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.170.00N/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)SNDLSNDL-$69.18M-$0.270.00N/AN/A-10.38%-8.58%-7.23%11/4/2025 (Estimated)Latest NVCT, MNPR, SNDL, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025MNPRMonopar Therapeutics-$0.48N/AN/AN/AN/AN/A11/4/2025Q3 2025NVCTNuvectis Pharma-$0.24N/AN/AN/AN/AN/A10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A7/31/2025Q2 2025SNDLSNDL-$0.04$0.01+$0.05$0.01$231.50 million$179.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82MNPRMonopar TherapeuticsN/A33.9333.93NVCTNuvectis PharmaN/A2.662.66SNDLSNDL0.115.033.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%MNPRMonopar Therapeutics1.83%NVCTNuvectis Pharma96.77%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%MNPRMonopar Therapeutics20.50%NVCTNuvectis Pharma30.52%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableSNDLSNDL2,516262.78 millionN/AOptionableNVCT, MNPR, SNDL, and CMPS HeadlinesRecent News About These CompaniesSNDL to Release Q3 2025 Financial Results on November 4October 15 at 5:31 PM | tipranks.comSNDL to Announce Third Quarter 2025 Financial Results on November 4, 2025October 15 at 4:30 PM | globenewswire.comSNDL (NASDAQ:SNDL) Stock Price Down 7.6% - Here's WhyOctober 11, 2025 | marketbeat.comHot Picks: Investor optimism returns as cannabis sector shows signs of recoveryOctober 10, 2025 | bnnbloomberg.caBSNDL (NASDAQ:SNDL) Hits New 52-Week High - Here's What HappenedOctober 10, 2025 | marketbeat.comSNDL's (SNDL) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Trading Up 5.3% - Here's WhyOctober 7, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Downgraded to Hold Rating by Wall Street ZenOctober 4, 2025 | marketbeat.comMarket-Beating SNDL Inc. (SNDL) Attracts Stake Boost From Goldman SachsSeptember 29, 2025 | msn.comSNDL (NASDAQ:SNDL) Reaches New 1-Year High Following Analyst UpgradeSeptember 29, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Stock Rating Upgraded by Wall Street ZenSeptember 26, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Trading Down 4.7% - Here's WhySeptember 26, 2025 | marketbeat.comBest Cannabis Stocks in Canada to Watch Now: Technical Signals and Market OutlookSeptember 18, 2025 | marijuanastocks.comMSNDL Releases Second Quarter 2025 Financial and Operational ResultsSeptember 16, 2025 | insidermonkey.comSNDL Is Up Too MuchSeptember 14, 2025 | seekingalpha.com3 Marijuana Stocks For Better Gains This MonthSeptember 12, 2025 | marijuanastocks.comMThe Best Cheap Stocks Under $10 to BuySeptember 10, 2025 | zacks.comAlliance Global Partners Initiates Coverage of SNDL (SNDL) with Buy RecommendationSeptember 4, 2025 | msn.comSNDL initiated with a Buy at Alliance Global PartnersSeptember 3, 2025 | msn.comMichigan Cannabis Retailer Case Ruling Codifies Receiver PowerAugust 29, 2025 | news.bloomberglaw.comNHow’s the Market Reacting to SNDL Inc’s (SNDL) Q2 Results?August 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCT, MNPR, SNDL, and CMPS Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$6.52 +0.11 (+1.72%) Closing price 04:00 PM EasternExtended Trading$6.52 0.00 (-0.08%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Monopar Therapeutics NASDAQ:MNPR$80.13 -2.43 (-2.94%) Closing price 04:00 PM EasternExtended Trading$80.08 -0.05 (-0.06%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Nuvectis Pharma NASDAQ:NVCT$6.17 +0.08 (+1.31%) Closing price 04:00 PM EasternExtended Trading$6.14 -0.03 (-0.41%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.SNDL NASDAQ:SNDL$2.33 -0.05 (-2.10%) Closing price 04:00 PM EasternExtended Trading$2.35 +0.02 (+0.64%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
